Last reviewed · How we verify
Typhoid Vi vaccine
The Typhoid Vi vaccine stimulates the immune system to produce antibodies and cellular immunity against Salmonella typhi by presenting the bacterial Vi polysaccharide capsular antigen.
The Typhoid Vi vaccine stimulates the immune system to produce antibodies and cellular immunity against Salmonella typhi by presenting the bacterial Vi polysaccharide capsular antigen. Used for Prevention of typhoid fever caused by Salmonella typhi in travelers and at-risk populations.
At a glance
| Generic name | Typhoid Vi vaccine |
|---|---|
| Also known as | Typherix |
| Sponsor | International Vaccine Institute |
| Drug class | polysaccharide vaccine |
| Target | Salmonella typhi Vi polysaccharide capsular antigen |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains purified Vi polysaccharide from the outer capsule of Salmonella typhi, which is recognized by B cells to generate protective antibodies and by T cells to establish cellular immunity. This immune response prevents infection when exposed to wild-type typhoid bacteria. The Vi antigen is a key virulence factor that protects the bacteria from complement-mediated killing, making it an effective immunogenic target.
Approved indications
- Prevention of typhoid fever caused by Salmonella typhi in travelers and at-risk populations
Common side effects
- Injection site pain or erythema
- Headache
- Myalgia
- Fever
- Nausea
Key clinical trials
- Vellore Typhoid Vaccine Impact Trial (PHASE4)
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants (PHASE2)
- Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children (PHASE2)
- Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women (NA)
- Opportunistic Pneumococcal Immunisation Trial in MALnutrition (PHASE4)
- Inflammatory Challenge and Fear (PHASE1)
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Typhoid Vi vaccine CI brief — competitive landscape report
- Typhoid Vi vaccine updates RSS · CI watch RSS
- International Vaccine Institute portfolio CI